Insider Trading Alert - CRL, IDA And DAL Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 27, 2014, 119 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $99.26 to $40,800,000.00.

Highlighted Stocks Traded by Insiders:

Charles River Laboratories International In (CRL) - FREE Research Report

Geller Jorg who is Corporate Executive VP at Charles River Laboratories International In sold 3,188 shares at $58.49 on Feb. 27, 2014. Following this transaction, the Corporate Executive VP owned 50,235 shares meaning that the stake was reduced by 5.97% with the 3,188-share transaction.

The shares most recently traded at $60.45, up $1.96, or 3.25% since the insider transaction. Historical insider transactions for Charles River Laboratories International In go as follows:

  • 4-Week # shares sold: 36,796
  • 12-Week # shares sold: 39,946
  • 24-Week # shares sold: 68,802

The average volume for Charles River Laboratories International In has been 529,900 shares per day over the past 30 days. Charles River Laboratories International In has a market cap of $2.9 billion and is part of the health care sector and drugs industry. Shares are up 14.06% year-to-date as of the close of trading on Thursday.

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. The company has a P/E ratio of 27.7. Currently there are 5 analysts that rate Charles River Laboratories International In a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRL - FREE

TheStreet Quant Ratings rates Charles River Laboratories International In as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Charles River Laboratories International In Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Advanced Micro Devices, Micron Technology, Charles River Labs: 'Mad Money' Lightning Round

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)

Parexel Is Discovering the Drugs of the Future

Analysts' Actions -- GE, Nordstrom, Coca-Cola, Eli Lilly and More

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

Trader's Daily Notebook: For a Decline, It Sure Was Smooth